Effect of selective serotonin reuptake inhibitors of platelet activation: Can they prevent acute myocardial infarction?

American Journal of Cardiovascular Drugs

Volumn 3, Issue 3, 2003, Pages 149-162

  Schlienger, Raymond G ^a,b   Meier, Christoph R ^a,c  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; AMITRIPTYLINE; AMOXAPINE; CATECHOLAMINE; CITALOPRAM; CLOMIPRAMINE; CLOVOXAMINE; DESIPRAMINE; DOSULEPIN; DOXEPIN; FLUOXETINE; FLUVOXAMINE; LITHIUM; MAPROTILINE; MIANSERIN; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN; NORTRIPTYLINE; PADGEM PROTEIN; PAROXETINE; SEROTONIN; SEROTONIN 2 RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TETRACYCLIC ANTIDEPRESSANT AGENT; THROMBOXANE B2; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

BLEEDING DISORDER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DEPRESSION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ECCHYMOSIS; EPISTAXIS; HEART INFARCTION; HEMORRHOID; HUMAN; MELENA; MENORRHAGIA; PETECHIA; PRIORITY JOURNAL; REVIEW; SEROTONIN BLOOD LEVEL; THROMBOCYTE ACTIVATION; UPPER GASTROINTESTINAL BLEEDING;

EID: 0037963599     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200303030-00001     Document Type: Review

References (115)

1. Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: epidemiology. biology, and treatment. Arch Gen Psychiatry 1998; 55 (7): 580-92
2. Jiang W, Krishnan RR, O'Connor CM. Depression and heart disease: evidence of a link, and its therapeutic implications. CNS Drugs 2002; 16 (2): 111-27
3. Rozanski A, Blumenthal JA, Kaplan J. Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. Circulation 1999; 99 (16): 2192-217
4. Hayward C. Psychiatric illness and cardiovascular disease risk. Epidemiol Rev 1995; 17 (1): 129-38
5. Cohen HW, Gibson G, Alderman MH. Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents. Am J Med 2000; 108 (1): 2-8
6. Barbey JT, Roose SP. SSRI safety in overdose. J Clin Psychiatry 1998; 59 Suppl. 15: 42-8
7. Rickels K, Schweizer E. Clinical overview of serotonin reuptake inhibitors. J Clin Psychiatry 1990; 51 Suppl. B: 9-12
8. Kasper S. Fuger J, Moller HJ. Comparative efficacy of antidepressants. Drugs 1992; 43 Suppl. 2: 11-22
9. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000; 58 (1): 19-36
10. Celada P, Dolera M, Alvarez E, et al. Effects of acute and chronic treatment with fluvoxamine on extracellular and platelet serotonin in the blood of major depressive patients: relationship to clinical improvement. J Affect Disord 1992; 25 (4): 243-50
11. Menys VC, Smith CCT, Lcwins P, et al. Platelet 5-hydroxytryptamine is decreased in a preliminary group of depressed patients receiving the 5-hydroxytryptamine re-uptake inhibiting drug fluoxetine. Clin Sci 1996; 91 (1): 87-92
12. Hergovich N, Aigner M, Eichler HG, et al. Paroxetine decreases platelet serotonin storage and platelet function in human beings. Clin Pharmacol Ther 2000; 68 (4): 435-42
13. De Clerck F. The role of serotonin in thrombogenesis. Clin Physiol Biochem 1990; 8 Suppl. 3: 40-9
14. Skop BP, Brown TM. Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors. Psychosomatics 1996; 37 (1): 12-6
15. Alderman CP, Moritz CK, Ben-Tovim DI. Abnormal platelet aggregation associated with fluoxetine therapy. Ann Pharmacother 1992; 26 (12): 1517-9
16. Aranth J, Lindberg C. Bleeding, a side effect of fluoxetine [letter]. Am J Psychiatry 1992: 149 (3): 412
17. Cooper TA, Valcour VG, Gibbons RB, et al. Spontaneous ecchymoses due to paroxetine administration. Am J Med 1998; 104 (2): 197-8
18. Evans TG, Buys SS, Rodgers GM. Acquired abnormalities in platelet function [letter]. N Engl J Med 1991; 324 (23): 1671
19. Gunzberger DW, Martinez D. Adverse vascular effects associated with fluoxetine [letter]. Am J Psychiatry 1992; 149 (12): 1751
20. Humphries JE, Wheby MS, VandenBerg SR. Fluoxetine and the bleeding time. Arch Pathol Lab Med 1990; 114 (7): 727-8
21. Ottervanger JP, Stricker BHC, Huls J, et al. Bleeding attributed to the intake of paroxetine. Am J Psychiatry 1994; 151 (5): 781-2
22. Shader RI, Greenblatt DJ. Selective serotonin reuptake inhibitor antidepressants: cardiovascular complications: sorting through findings. J Clin Psychopharmacol 2001; 21 (5): 467-8
23. Zarzar MN, Kingsley RS. Use of fluoxetine in a person with cardiac arrhythmias. Psychosomatics 1990: 31 (2): 235-6
24. Ellison JM, Milofsky JE, Ely E. Fluoxetine-induced bradycardia and syncope in two patients. J Clin Psychiatry 1990; 51 (9): 385-6
25. Buff DD, Brenner R, Kirtane SS, et al. Dysrhythmia associated with fluoxetine treatment in an elderly patient with cardiac disease. J Clin Psychiatry 1991; 52 (4): 174-6
26. Rodriguez de la Torre B. Dreher J, Malevany I, et al. Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients. Ther Drug Monit 2001; 23 (4): 435-40
27. Shapiro PA, Lesperance F, Frasure-Smith N, et al. An open-label preliminary trial of sertraline treatment of major depression after acute myocardial infarction (the SADHAT trial). Sertraline Anti-Depressant Heart Attack trial. Am Heart J 1999; 137 (6): 1100-6
28. Rouse SP, Laghrissi-Thode F, Kennedy JS, et al. Comparison of paroxetipe and nortriptyline in depressed patients with ischemic heart disease. JAMA 1998; 279 (4): 287-91
29. Strik JJ, Honig A, Lousberg R, et al. Cardiac side-effects of two selective serotonin reuptake inhibitors in middle-aged and elderly depressed patients. Int Clin Psychopharmacol 1998; 13 (6): 263-7
30. Strik JJ, Honig A, Lousberg R, et al. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosom Med 2000; 62 (6): 783-9
31. Malzberg B. Mortality among patients with involution melancholia. Am J Psychiatry 1937; 93: 1231-8
32. Glassman AH, Shapiro PA. Depression and the course of coronary artery disease. Am J Psychiatry 1998; 155 (1): 4-11
33. Weeke A, Juel K, Vaeth M. Cardiovascular death and manic-depressive psychosis. J Affect Disord 1987; 13 (3): 287-92
34. Hallstrom T, Lapidus L, Bengtsson C, et al. Psychosocial factors and risk of ischaemic heart disease and death in women: a twelve-year follow-up of participants in the population study of women in Gothenburg, Sweden. J Psychosom Res 1986, 30 (4): 451-9
35. Appels A, Mulder P. Excess fatigue as a precursor of myocardial infarction. Eur Heart J 1988; 9 (7): 758-64
36. Anda R, Williamson D, Jones D, et al. Depressed affect, hopelessness, and the risk of ischemic heart disease in a cohort of US adults. Epidemiology 1993; 4 (4): 285-94
37. Aromaa A, Raitasalo R, Reunanen A, et al. Depression and cardiovascular diseases. Acta Psychiatr Scand Suppl 1994; 377: 77-82
38. Simonsick EM, Wallace RB, Blazer DG, et al. Depressive symptomatology and hypertension-associated morbidity and mortality in older adults. Psychosom Med 1995; 57 (5): 427-35
39. Everson SA, Goldberg DE, Kaplan GA, et al. Hopelessness and risk of mortality and incidence of myocardial infarction and cancer. Psychosom Med 1996; 58: 113-21
40. Wassertheil-Smoller S, Applegate WB, Berge K, et al. Change in depression as a precursor of cardiovascular events: SHEP Cooperative Research Group (Systolic Hypertension in the elderly). Arch Intern Med 1996; 156 (5): 553-61
41. Barefoot JC, Schroll M. Symptoms of depression, acute myocardial infarction, and total mortality in a community sample. Circulation 1996; 93 (11): 1976-80
42. Pratt LA, Ford DE, Crum RM, et al. Depression, psychotropic medication, and risk of myocardial infarction: prospective data from the Baltimore ECA follow-up. Circulation 1996; 94 (12): 3123-9
43. Ford DE, Mead LA, Chang PP, et al. Depression is a risk factor for coronary artery disease in men. Arch Intern Med 1998; 158 (13): 1422-6
44. Mendes de Leon CF, Krumholz HM, Seeman TS, et al. Depression and risk of coronary heart disease in elderly men and women: New Haven EPESE, 1982-1991: established populations for the epidemiologic studies of the elderly. Arch Intern Med 1998; 158 (21): 2341-8
45. Ariyo AA, Haari M, Tangen CM, et al. Depressive symptoms and risks of coronary heart disease and mortality in elderly Americans: Cardiovascular Health Study Collaborative Research Group. Circulation 2000; 102 (15): 1773-9
46. Ferketich AK, Schwartzbaum JA, Frid DJ, et al. Depression as an antecedent to heart disease among women and men in the NHANES I study: National Health and Nutrition Examination Survey. Arch Intern Med 2000; 160 (9): 1261-8
47. Penninx BW, Beekman AT, Honig A, et al. Depression and cardiac mortality: results from a community-based longitudinal study. Arch Gen Psychiatry 2001; 58 (3): 221-7
48. Murphy JM, Monson RR, Olivier DC, et al. Affective disorders and mortality: a general population study. Arch Gen Psychiatry 1987; 44 (5): 473-80
49. Vogt T, Pope C, Mullooly J, et al. Mental health status as a predictor of morbidity and mortality: a 15-year follow-up of a health maintenance organization. Am J Public Health 1994; 84 (2): 227-31
50. Kubzansky LD, Kawachi I, Spiro III A, et al. Is worrying bad for your heart?.: a prospective study of worry and coronary heart disease in the Normative Aging Study. Circulation 1997; 95 (4): 818-24
51. Strik JJ, Honig A, Maes M. Depression and myocardial infarction: relationship between heart and mind. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25 (4): 879-92
52. Forrester AW, Lipsey JR, Teitelbaum ML, et al. Depression following myocardial infarction. Int J Psychiatry Med 1992: 22 (1): 33-46
53. Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial intarction: impact on 6-month Survival. JAMA 1993; 270 (15): 1819-25
54. Frasure-Smith N, Lesperance F, Talajic M. Depression and 18-month prognosis after myocardial infarction. Circulation 1995; 91 (4): 999-1005
55. Schleifer SJ, Macari-Hinson MM, Coyle DA, et al. The nature and course of depression following myocardial infarction. Arch Intern Med 1989; 149 (8): 1785-9
56. Irvine J, Basinski A, Baker B, et al. Depression and risk of sudden cardiac death after acute myocardial infarction: testing for the confounding effects of fatigue. Psychosom Med 1999; 61 (6): 729-37
57. Lane D, Carroll D, Ring C, et al. Mortality and quality of life 12 months after myocardial infarction: effects of depression and anxiety. Psychosom Med 2001; 63 (2): 221-30
58. Frasure-Smith N, Lesperance F, Juneau M, et al. Gender, depression, and one-year prognosis after myocardial infarction. Psychosom Med 1999; 61 (1): 26-37
59. Ladwig KH, Roll G, Breithardt G, et al. Post-infarction depression and incomplete recovery 6 months after acute myocardial infarction. Lancet 1994; 343 (8888): 20-3
60. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995; 332 (23): 1553-9
61. Nemeroff CB, Musselman DL. Are platelets the link between depression and ischemic heart disease? Am Heart J 2000: 140 (4 Suppl.): 57-62
62. Musselman DL, Tomer A, Manatunga AK, et al. Exaggerated platelet reactivity in major depression. Am J Psychiatry 1996; 153 (10): 1313-7
63. Markovitz JH, Matthews KA. Platelets and coronary heart disease: potential psychophysiologic mechanisms. Psychosom Med 1991; 53 (6): 643-68
64. De Clerck F. Effects of serotonin on platelets and blood vessels. J Cardiovasc Pharmacol 1991; 17 Suppl. 5: S1-5
65. Laghrissi-Thode F, Wagner WR, Pollock BG, et al. Elevated platelet factor 4 and beta-thromboglobulin plasma levels in depressed patients with ischemic heart disease. Biol Psychiatry 1997; 42 (4): 290-5
66. Lederbogen F, Gilles M, Maras A, et al. Increased platelet aggregability in major depression? Psychiatry Res 2001; 102 (3): 255-61
67. Blardi P, De Lalla A, Leo A, et al. Serotonin and fluoxetine levels in plasma and platelets after fluoxetine treatment in depressive patients. J Clin Psychopharmacol 2002; 22 (2): 131-6
68. Walsh MT, Dinan TG, Condren RM, et al. Depression is associated with an increase in the expression of the platelet adhesion receptor glycoprotein Ib. Life Sci 2002; 70 (26): 3155-65
69. Biegon A, Essar N, Israeli M, et al. Serotonin 5-HT2 receptor binding on blood platelets as a state dependent marker in major affective disorder. Psychopharmacology 1990; 102 (1): 73-5
70. Biegon A, Weizman A, Karp L, et al. Serotonin 5-HT2 receptor binding on blood platelets: a peripheral marker for depression? Life Sci 1987; 41 (22): 2485-92
71. Arora RC, Meltzer HY. Increased serotonin (5-HT2) receptor binding as measured by 3H-lysergic acid diethylamide (3H-LSD) in the blood platelets of depressed patients. Life Sci 1989; 44 (11): 725-34
72. Nemeroff CB, Widerlov E, Bissette G, et al. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 1984; 226 (4680): 1342-4
73. Banki CM, Bissette G, Arato M, et al. CSF corticotropin-releasing factor-like immunoreactivity in depression and schizophrenia. Am J Psychiatry 1987; 144 (7): 87-7
74. France RD, Urban B, Krishnan KR, et al. CSF corticotropin-releasing factor-like immunoactivity in chronic pain patients with and without major depression. Biol Psychiatry 1988; 23 (1): 86-8
75. Carroll BJ, Curtis GC, Davies BM, et al. Urinary free cortisol excretion in depression. Psychol Med 1976: 6 (1): 43-50
76. Gold PW, Loriaux DL, Roy A, et al. Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing's disease: pathophysiologic and diagnostic implications. N Engl J Med 1986; 314 (21): 1329-35
77. Schlechte JA, Coffman T. Plasma free cortisol in depressive illness: a review of findings and clinical implications. Psychiatr Med 1985; 3 (1): 23-31
78. Weber-Hamann B, Hentschel F, Kniest A, et al. Hypercortisolemic depression is associated with increased intra-abdominal fat. Psychosom Med 2002; 64 (2): 274-7
79. Wyatt RJ, Portnoy B, Kupfer DJ, et al. Resting plasma catecholamine concentrations in patients with depression and anxiety. Arch Gen Psychiatry 1971; 24 (1): 65-70
80. Veith RC, Lewis N, Linares OA, et al. Sympathetic nervous system activity in major depression: basal and desipramine-induced alterations in plasma norepinephrine kinetics. Arch Gen Psychiatry 1994; 51 (5): 411-22
81. Anfossi G, Trovati M. Role of catecholamines in platelet function: pathophysiological and clinical significance. Eur J Clin Invest 1996; 26 (5): 353-70
82. Shores MM, Pascualy M, Lewis NL, et al. Short-term sertraline treatment suppresses sympathetic nervous system activity in healthy human subjects. Psychoneuroendocrinology 2001; 26 (4): 433-9
83. Calhoun JW, Calhoun DD. Prolonged bleeding time in a patient treated with sertraline [letter]. Am J Psychiatry 1996; 153: 443
84. Tielens JA. Vitamin C for paroxetine- and fluvoxamine-associated bleeding. Am J Psychiatry 1997; 154 (6): 883-4
85. Wilmshurst PT, Kumar AV. Subhyaloid haemorrhage with fluoxetine [letter]. Eye 1996: 10 (Pt 1): 141
86. Leung M, Shore R. Fluvoxamine-associated bleeding. Can J Psychiatry 1996; 41 (9): 604-5
87. Mhanna MJ. Bennet II JB, Izatt SD. Potential fluoxetine chloride (Prozac) toxicity in a newborn. Pediatrics 1997; 100 (1): 158-9
88. Yaryura-Tobias JA, Kirschen H, Ninan P, et al. Fluoxetine and bleeding in obsessive-compulsive disorder [letter]. Am J Psychiatry 1991; 148 (7): 949
89. Lake MB, Birmhaher B, Wassick S, et al. Bleeding and selective serotonin reuptake inhibitors in childhood and adolescence. J Child Adolesc Psychopharmacol 2000; 10: 35-8
90. Berg C, Couturier F, Grass F, et al. Saignements sous inhibiteurs de la recapture de la sérotonine: à propos d'un cas clinique. Therapie 2001; 56 (1): 65-7
91. Nelva A, Guy C, Tardy-Poncet B, et al. Syndrômes hémorragiques sous antidépresseurs inhibiteurs sélectifs de la recapture de la sérotonine (ISRS): a propos de sept cas et revue de la littérature. Rev Med Interne 2000; 21 (2): 152-60
92. Vandel P, Vandel S, Kantelip JP. Saignements et inhibiteurs de la recapture de la sérotonine: à propos de deux cas. Therapie 2001; 56 (4): 445-7
93. de Abajo FJ, Garcia Rodriguez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population bascd case-control Study. BMJ 1999; 319 (7217): 1106-9
94. de Abajo F, Jick H, Derby L, et al. Intracranial haemorrhage and use of selective serotonin reuptake inhibitors. Br J Clin Pharmacol 2000; 50 (1): 43-7
95. Bak S, Tsiropoulos I, Kjaersgaard JO, et al. Selective serotonin reuptake inhibitors and the risk of stroke: a population-based case-control study. Stroke 2002; 33 (6): 1465-73
96. Layton D, Clark DW, Pearce GL, et al. Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding?.: results from a cohort study based on prescription event monitoring in England. Eur J Clin Pharmacol 2001; 57 (2): 167-76
97. van Walraven C, Maindani MM, Wells PS, et al. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. BMJ 2001; 323 (7314): 655-8
98. Markovitz JH, Shuster JL, Chitwood WS, et al. Platelet activation in depression and effects of sertraline treatment: an open-label study. Am J Psychiatry 2000; 157 (6): 1006-8
99. Musselman DL, Marzec UM, Manatunga A, et al. Platelet reactivity in depressed patients treated with paroxetine: preliminary findings. Arch Gen Psychiatry 2000: 57 (9): 875-82
100. Pollock BG, Laghrissi-Thode F, Wagner WR. Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. J Clin Psychopharmacol 2000: 20 (2): 137-40
101. Serebruany VL, Gurbel PA, O'Connor CM. Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors. Pharmacol Res 2001; 43 (5): 453-62
102. Muck-Seler D, Jakovljevic M, Deanovic Z. Effect of antidepressant treatment on platelet 5-HT content and relation to therapeutic outcome in unipolar depressive patients. J Affect Disord 1991; 23 (3): 157-64
103. Javors MA, Houston JP, Tekell JL, et al. Reduction of platelet serotonin content in depressed patients treated with either paroxetine or desipramine. Int J Neuropsychopharmacol 2000; 3 (3): 229-35
104. Nair GV, Gurbel PA, O'Connor CM, et al. Depression, coronary events, platelet inhibition, and serotonin reuptake inhibitors. Am J Cardiol 1999; 84 (3): 321-3
105. Glassman AH, Rodriguez AI, Shapiro PA. The use of antidepressant drugs in patients with heart disease. J Clin Psychiatry 1998; 59 Suppl. 10: 16-21
106. Roose SP, Glassman AH, Attia E, et al. Cardiovascular effects of fluoxetine in depressed patients with heart disease. Am J Psychiatry 1998; 155 (5): 660-5
107. Meier CR, Schlienger RG, Jick H. Use of selective serotonin reuptake inhibitors and risk of developing first-time acute myocardial infarction. Br J Clin Pharmacol 2001; 52 (2): 179-84
108. Sauer WH, Berlin JA, Kimmel SE. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation 2001; 104 (16): 1894-8
109. Barefoot JC, Williams RB. Antidepressant use and the risk of myocardial infarction. Am J Med 2000; 108 (1): 87-8
110. Walley T, Mantgani A. The UK general practice research database. Lancet 1997; 350 (9084): 1097-9
111. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerized data resource in the United Kingdom. BMJ 1991; 302 (6779): 766-8
112. Jick H, Terris BZ, Derby LE, et al. Further validation of information recorded on a general practitioner based computerized data resource in the United Kingdom. Pharmacoepidemiol Drug Saf 1992; 1: 347-9
113. Garcia Rodriguez LA, Perez Gutthann S. Use of the UK general practice research database for pharmacoepidemiology. Br J Clin Pharmacol 1998; 45 (5): 419-25
114. Kimmel SE, Berlin JA, Miles C, et al. Risk of acute first myocardial infarction and use of nicotine patches in a general population. J Am Coll Cardiol 2001; 37 (5): 1297-302
115. Glassman AH, O'Connor CM, Califf RM. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002; 288 (6): 701-9